Literature DB >> 12819326

Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors?

Stephen I-Hong Hsu1, William G Couser.   

Abstract

The mechanisms by which increased urinary protein concentrations lead to nephrotoxic injury are certain to be multifactorial and involve complex interactions between numerous pathways of cellular damage mediated by both cellular and humoral pathways. These may include a major role for the podocyte in glomerular diseases leading to chronic renal failure, the loss of microvascular endothelium, the albumin-induced upregulation of renal cytokines and growth factors that promote tubulointerstitial injury by inflammation and fibrogenesis, and the role of complement-mediated tubulointerstitial injury due to proteinuria. This review will focus on the last mechanism, and emphasize recent studies implicating a primary role for activation of complement in proteinuric urine as the principal mediator of tubulointerstitial damage and progressive renal disease in various experimental animal models of nephrosis. It will be our contention that intraluminal activation of the terminal complement cascade leading to the formation of the C5b-9 membrane attack complex is the principal mediator of chronic progressive interstitial damage and progressive renal failure irrespective of the type of primary glomerular injury. This paradigm has important implications for the potential therapeutic role of complement inhibitors that are currently being developed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12819326     DOI: 10.1097/01.asn.0000070032.58017.20

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  26 in total

Review 1.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

Review 2.  Role of complement 3 in the pathogenesis of hypertension.

Authors:  Lan Chen; Noboru Fukuda; Taro Matsumoto; Masanori Abe
Journal:  Hypertens Res       Date:  2019-12-18       Impact factor: 3.872

3.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

4.  Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Jelleke J Hakvoort; Gerjan J Navis; Harry van Goor; Mohamed R Daha; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

5.  Therapeutic advantage of angiotensin-converting enzyme inhibitors in patients with proteinuric chronic kidney disease.

Authors:  Kiyotsugu Omae; Tetsuya Ogawa; Kosaku Nitta
Journal:  Heart Vessels       Date:  2010-05-29       Impact factor: 2.037

6.  Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury.

Authors:  Mauro Abbate; Carla Zoja; Daniela Corna; Daniela Rottoli; Cristina Zanchi; Nadia Azzollini; Susanna Tomasoni; Silvia Berlingeri; Marina Noris; Marina Morigi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2008-03-19       Impact factor: 10.121

Review 7.  All Things Complement.

Authors:  Joshua M Thurman; Carla M Nester
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-23       Impact factor: 8.237

Review 8.  Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology.

Authors:  Erik I Christensen; Jakub Gburek
Journal:  Pediatr Nephrol       Date:  2004-05-14       Impact factor: 3.714

Review 9.  Proteinuria and progression of glomerular diseases.

Authors:  Elif Erkan
Journal:  Pediatr Nephrol       Date:  2012-11-03       Impact factor: 3.714

10.  Mannose-Binding Lectin and Diabetic Nephropathy in Type 1 Diabetes.

Authors:  Shi-Qi Zhao; Zhao Hu
Journal:  J Clin Lab Anal       Date:  2015-07-24       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.